Ida G.
- Country
- Denmark
- Department
- Digestive Disease Center
Research Overview
- Phase 3b, Randomized, Open‑Label, Active‑Controlled Trial Comparing Guselkumab Versus Risankizumab for Efficacy and Safety in Moderately to Severely Active Crohn’s Disease
- A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients with Fibrostenotic Crohn’s Disease
- Evaluation of Efavaleukin Alfa for Induction Therapy in Moderately to Severely Active Ulcerative Colitis: A Phase 2 Randomized, Double-blind, Placebo-controlled Study
Data & Insights
Has run more than one trial at 72 of 159 partner sites.
Specializations
Gastroenterology Research
This investigator specializes in studying fibrostenotic Crohn's disease, focusing on innovative therapeutic approaches for patients with advanced intestinal complications.
- Inflammatory Bowel Disease Management
- Intestinal Fibrosis
- Gastrointestinal Stenosis
Their research encompasses evaluation of novel therapeutic agents for managing gastrointestinal tract complications associated with Crohn's disease.
Therapeutic Development
The investigator's work centers on assessing new therapeutic interventions for chronic inflammatory conditions affecting the digestive system.
- Treatment Safety Assessment
- Clinical Efficacy Studies
- Patient Response Evaluation
Their expertise extends to evaluating therapeutic outcomes in patients with complex gastrointestinal disorders.
Clinical Innovation
The investigator focuses on advancing treatment options for patients with complicated inflammatory bowel conditions.
- Novel Treatment Approaches
- Disease Progression Management
- Therapeutic Response Monitoring
Their research aims to improve treatment outcomes for patients with advanced gastrointestinal complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.